| $687M | ||
| $385M | ||
| $215M | ||
| $100M | ||
| $87M | ||
| $82M |
Buys | $0 | 0 | 0 |
Sells | $1,708,434 | 9 | 100 |
| Ceesay Abraham | director | 0 | $0 | 1 | $64,005 | $-64,005 |
| SLONIN JONATHAN | Chief Medical Officer | 0 | $0 | 2 | $111,570 | $-111,570 |
| BIGAL MARCELO | director | 0 | $0 | 1 | $116,267 | $-116,267 |
| RIKER LAUREN | Senior Vice President, Finance | 0 | $0 | 1 | $146,208 | $-146,208 |
| WILLIAMS KRISTEN | Chief Administrative Officer | 0 | $0 | 1 | $377,226 | $-377,226 |
| Cross Shawn | Chief Financial Officer | 0 | $0 | 3 | $893,157 | $-893,157 |
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Over the last 12 months, insiders at Pacira BioSciences, Inc. have bought $0 and sold $1.71M worth of Pacira BioSciences, Inc. stock.
On average, over the past 5 years, insiders at Pacira BioSciences, Inc. have bought $215,684 and sold $9.76M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,512 shares for transaction amount of $20,034 was made by BIGAL MARCELO (director) on 2024‑08‑16.
| 2025-12-10 | Sale | Cross Shawn | Chief Financial Officer | 9,104 0.0203% | $25.14 | $228,875 | +4.49% | |
| 2025-12-09 | Sale | Cross Shawn | Chief Financial Officer | 15,896 0.0353% | $25.03 | $397,877 | +5.38% | |
| 2025-11-17 | Sale | SLONIN JONATHAN | Chief Medical Officer | 3,960 0.0088% | $24.09 | $95,396 | +1.83% | |
| 2025-11-10 | Sale | Cross Shawn | Chief Financial Officer | 12,060 0.0266% | $22.09 | $266,405 | +4.55% | |
| 2025-09-04 | Sale | Ceesay Abraham | director | 2,354 0.0053% | $27.19 | $64,005 | -10.68% | |
| 2025-08-07 | Sale | BIGAL MARCELO | director | 4,912 0.0109% | $23.67 | $116,267 | +3.41% | |
| 2025-06-04 | Sale | WILLIAMS KRISTEN | Chief Administrative Officer | 14,376 0.0302% | $26.24 | $377,226 | -11.42% | |
| 2025-06-04 | Sale | RIKER LAUREN | Senior Vice President, Finance | 5,578.34 0.0117% | $26.21 | $146,208 | -11.42% | |
| 2025-01-06 | Sale | SLONIN JONATHAN | Chief Medical Officer | 879 0.0019% | $18.40 | $16,174 | +31.62% | |
| 2024-12-13 | Sale | GAUGLER DARYL | Chief Operating Officer | 500 0.0011% | $19.76 | $9,880 | +22.56% | |
| 2024-09-13 | Sale | GAUGLER DARYL | Chief Operating Officer | 500 0.0011% | $12.86 | $6,430 | +78.49% | |
| 2024-08-16 | Brege Laura | director | 1,000 0.0023% | $12.81 | $12,810 | +76.51% | ||
| 2024-08-16 | BIGAL MARCELO | director | 1,512 0.0036% | $13.25 | $20,034 | +76.51% | ||
| 2024-08-14 | YANG MICHAEL J. | director | 2,000 0.0046% | $12.90 | $25,800 | +82.12% | ||
| 2024-08-12 | Lee Frank D. | Chief Executive Officer | 8,264 0.0178% | $12.10 | $99,994 | +83.69% | ||
| 2024-08-12 | Froimson Mark | director | 1,400 0.0029% | $11.58 | $16,212 | +83.69% | ||
| 2024-08-12 | BIGAL MARCELO | director | 3,400 0.0073% | $12.01 | $40,834 | +83.69% | ||
| 2024-08-02 | Sale | SLONIN JONATHAN | Chief Medical Officer | 945 0.0019% | $20.05 | $18,947 | +5.17% | |
| 2024-07-02 | Sale | SLONIN JONATHAN | Chief Medical Officer | 2,836 0.0062% | $28.25 | $80,117 | -6.79% | |
| 2024-06-13 | Sale | GAUGLER DARYL | Chief Operating Officer | 1,000 0.0021% | $28.38 | $28,380 | -25.29% |
| SLONIN JONATHAN | Chief Medical Officer | 178367 0.3921% | $4.67M | 0 | 9 | |
| WILLIAMS KRISTEN | Chief Administrative Officer | 161574 0.3552% | $4.23M | 0 | 32 | |
| RIKER LAUREN | Senior Vice President, Finance | 59564 0.1309% | $1.56M | 0 | 41 | |
| Cross Shawn | Chief Financial Officer | 56250 0.1237% | $1.47M | 0 | 3 | |
| BIGAL MARCELO | director | 11393 0.025% | $298,268.74 | 2 | 1 | +80.1% |
| Ceesay Abraham | director | 9039 0.0199% | $236,641.02 | 0 | 1 | |
| GORDON CARL L | director | 2828941 6.2192% | $74.06M | 1 | 0 | +33.11% |
| KAILIAN VAUGHN M | 2790479 6.1346% | $73.05M | 3 | 1 | +45.51% | |
| MPM BioVentures IV QP LP | 2790479 6.1346% | $73.05M | 3 | 1 | +45.51% | |
| ORBIMED ADVISORS LLC | 10 percent owner | 2446000 5.3773% | $64.04M | 1 | 9 | +33.11% |
| HBM Healthcare Investments (Cayman) Ltd. | 10 percent owner | 2233993 4.9112% | $58.49M | 2 | 6 | +43.57% |
| Wicki Andreas | director | 451324 0.9922% | $11.82M | 2 | 72 | +43.57% |
| Sanderling Venture Partners VI LP | director | 416083 0.9147% | $10.89M | 1 | 5 | +33.11% |
| STACK DAVID M | CEO and Chairman | 153781 0.3381% | $4.03M | 1 | 45 | +35.49% |
| GAUGLER DARYL | Chief Operating Officer | 115200 0.2533% | $3.02M | 0 | 8 | |
| Lee Frank D. | Chief Executive Officer | 107784 0.237% | $2.82M | 1 | 0 | +83.69% |
| WINSTON ROY | Chief Medical Officer | 52440 0.1153% | $1.37M | 1 | 9 | +64.83% |
| McLoughlin Dennis | Chief Customer Officer | 38115 0.0838% | $997,850.70 | 0 | 7 | |
| Reinhart Charles A. III | Chief Financial Officer | 33626 0.0739% | $880,328.68 | 0 | 7 | |
| Ellis Ronald J. Jr. | Chief Strategy Officer | 30909 0.068% | $809,197.62 | 0 | 2 | |
| REINHARDT MAX | President, Rest of World | 29225 0.0642% | $765,110.50 | 0 | 12 | |
| LARANJEIRA CHARLES ANTHONY | Chief Technical Officer | 25852 0.0568% | $676,805.36 | 0 | 6 | |
| Scibetta James S | President | 25118 0.0552% | $657,589.24 | 2 | 13 | +5.63% |
| Manning Donald C. | Chief Medical Officer | 23520 0.0517% | $615,753.60 | 0 | 2 | |
| PACE GARY W | director | 22127 0.0486% | $579,284.86 | 5 | 6 | +11.64% |
| LONGENECKER JOHN P PHD | 18823 0.0414% | $492,786.14 | 1 | 12 | <0.0001% | |
| Kronenfeld Mark A. | director | 17897 0.0393% | $468,543.46 | 5 | 2 | +14.69% |
| Brege Laura | director | 17552 0.0386% | $459,511.36 | 1 | 6 | +76.51% |
| Jones James B | SVP & Chief Medical Officer | 16823 0.037% | $440,426.14 | 2 | 2 | <0.0001% |
| Scranton Richard | Chief Scientific Officer | 16061 0.0353% | $420,476.98 | 0 | 5 | |
| Froimson Mark | director | 14473 0.0318% | $378,903.14 | 2 | 2 | +41.3% |
| MOLLOY ANTHONY | Chief Lgl & Compliance Officer | 12877 0.0283% | $337,119.86 | 0 | 7 | |
| HASTINGS PAUL J | director | 12724 0.028% | $333,114.32 | 1 | 18 | +79.52% |
| Braunstein Scott | SVP, Strategy & Corp. Dev. | 9982 0.0219% | $261,328.76 | 1 | 1 | <0.0001% |
| YANG MICHAEL J. | director | 7230 0.0159% | $189,281.40 | 1 | 0 | +82.12% |
| Weiland Robert J. | Chief Commercial Officer | 5088 0.0112% | $133,203.84 | 0 | 1 | |
| WINGER DENNIS L | director | 2645 0.0058% | $69,246.10 | 1 | 0 | <0.0001% |
| Markvicka Taunia | SVP, Chief Commercial Officer | 230 0.0005% | $6,021.40 | 1 | 4 | <0.0001% |
| EVNIN LUKE | director | 0 0% | $0 | 3 | 15 | +45.51% |
| MIDDLETON FRED A | director | 0 0% | $0 | 2 | 5 | +43.57% |
| PATOU GARY | Chief Medical Officer | 0 0% | $0 | 0 | 9 | |
| Pratt John | General Manager, San Diego | 0 0% | $0 | 0 | 5 |
$12,831,842 | 73 | 20.01% | $2.07B | |
$218,350,131 | 64 | 16.68% | $732.84M | |
$14,599,168 | 59 | 12.79% | $1.82B | |
$129,489,279 | 57 | 26.09% | $656.14M | |
Pacira BioSciences, Inc. (PCRX) | $102,709,455 | 46 | 30.55% | $1.19B |
$33,884,330 | 45 | 12.58% | $449.72M | |
$97,642,477 | 41 | -10.58% | $468M | |
$11,542,910 | 40 | 56.19% | $1.66B | |
$73,312,053 | 38 | -4.37% | $1.79B | |
$21,068,600 | 35 | 9.64% | $1.27B | |
$6,021,989 | 30 | -0.17% | $577.96M | |
$6,506,230 | 27 | -16.20% | $1.21B | |
$25,034,841 | 20 | 9.38% | $575.88M | |
$1,843,996 | 10 | 22.92% | $1.18B | |
$1,718,514 | 9 | 38.12% | $1.56B | |
$26,633,903 | 9 | 42.23% | $1.54B | |
$179,515 | 7 | 1.51% | $659.04M | |
$543,932 | 6 | -22.02% | $695.69M | |
$614,633 | 6 | 27.88% | $1.64B |
| Increased Positions | 103 | +34.56% | 5M | +9.11% |
| Decreased Positions | 130 | -43.62% | 7M | -13.93% |
| New Positions | 36 | New | 1M | New |
| Sold Out Positions | 34 | Sold Out | 3M | Sold Out |
| Total Postitions | 271 | -9.06% | 48M | -4.82% |
| Blackrock, Inc. | $192,869.00 | 17.06% | 7.34M | -459,831 | -5.9% | 2025-09-30 |
| Vanguard Group Inc | $136,644.00 | 12.09% | 5.2M | -208,397 | -3.85% | 2025-09-30 |
| Doma Perpetual Capital Management Llc | $71,018.00 | 6.28% | 2.7M | +897,255 | +49.73% | 2025-09-30 |
| Dimensional Fund Advisors Lp | $56,878.00 | 5.03% | 2.16M | +11,831 | +0.55% | 2025-09-30 |
| Renaissance Technologies Llc | $56,213.00 | 4.97% | 2.14M | -257,400 | -10.74% | 2025-09-30 |
| D. E. Shaw & Co., Inc. | $51,059.00 | 4.52% | 1.94M | -311,222 | -13.81% | 2025-09-30 |
| State Street Corp | $49,966.00 | 4.42% | 1.9M | -50,047 | -2.57% | 2025-09-30 |
| Balyasny Asset Management L.P. | $49,559.00 | 4.38% | 1.89M | -245,662 | -11.53% | 2025-09-30 |
| American Century Companies Inc | $36,241.00 | 3.21% | 1.38M | +196,000 | +16.57% | 2025-09-30 |
| Goldman Sachs Group Inc | $34,440.00 | 3.05% | 1.31M | +1,087 | +0.08% | 2025-09-30 |